Literature DB >> 25758078

Primary cerebral lymphomatoid granulomatosis progressing to methotrexate-associated lymphoproliferative disease under immunosuppressive therapy.

Hiroaki Tanaka1, Shogo Furukawa, Yusuke Takeda, Naomi Shimizu, Takeharu Kawaguchi, Chika Kawajiri, Shinichiro Hashimoto, Toshiyuki Takagi, Shoichi Ito, Satoshi Ota, Satoshi Kuwabara, Chiaki Nakaseko.   

Abstract

Lymphomatoid granulomatosis (LYG) is an angiocentric and angiodestructive lymphoproliferative disease involving extranodal sites. Although LYG cerebral lesions are usually located adjacent to LYG pulmonary lesions, few reports have described the occurrence of primary cerebral LYG. We herein discuss a case of a 40-year-old Japanese woman with primary cerebral LYG that caused various neurological symptoms for more than five years and progressed to methotrexate-associated lymphoproliferative disease under treatment with immunosuppressive therapy. This case suggests that primary cerebral LYG should be considered a lymphoid neoplasm manifesting as a primary brain tumor and a component of the differential diagnosis of chronic neuroinflammatory disorders.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25758078     DOI: 10.2169/internalmedicine.54.2399

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

1.  Lymphomatoid granulomatosis with pulmonary and gastrointestinal involvement.

Authors:  J H Kappen; H C T van Zaanen; S M Snelder; A J P van Tilburg; A Rudolphus
Journal:  BMJ Case Rep       Date:  2017-02-06

2.  Methotrexate-associated lymphoproliferative disorder with hypopituitarism and central diabetes insipidus.

Authors:  Misaki Aoshima; Koji Nagayama; Kei Takeshita; Hiroshi Ajima; Sakurako Orikasa; Ayana Iwazaki; Hiroaki Takatori; Yutaka Oki
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2019-10-12

3.  High-grade Primary Central Nervous System Lymphomatoid Granulomatosis: Successful Rituximab Monotherapy.

Authors:  Sakiko Harada; Jun Ando; Miki Ando; Hideaki Nitta; Tadaaki Inano; Yusuke Hirasawa; Yoshiki Furukawa; Shintaro Kinoshita; Akihide Kondo; Koichi Ohshima; Norio Komatsu
Journal:  Intern Med       Date:  2021-06-12       Impact factor: 1.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.